Methanone, (3'-chloro(1,1'-biphenyl)-4-yl)(1-(2-pyrimidinyl)-4-piperidinyl)-
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.